Impulsive Aggressive Behavior: Open-Label Treatment With Citalopram

Christopher Reist, MD; Katsura Nakamura, MA; Elahe Sagart, MD; Kenneth N. Sokolski, MD; and Ken A. Fujimoto, BA

Published: January 15, 2003

Article Abstract

Background: Results from open-label and placebo-controlled trials suggest that the selective serotonin reuptake inhibitors reduce impulsive aggressive behavior. The objective of this open-label study was to investigate whether citalopram treatment has anti-aggressive effect on impulsive aggressive subjects meeting DSM-IV criteria for a cluster B personality disorder or intermittent explosive disorder.

Method: In this 8-week trial, subjects were initiated on 20 mg/day of citalopram and titrated up to 60 mg/day by the fourth week, if tolerated. The primary outcome measure was the Overt Aggression Scale-Modified (OAS-M), a scale used to quantify verbal and physical aggression, subjective irritability, and overt irritability. Secondary outcome measures included the Barratt Impulsiveness Scale and Buss-Durkee Hostility Inventory.

Results: Of 25 subjects enrolled, 20 completed the study. The mean daily dose was 45.5 mg, and citalopram was generally well tolerated. Statistically significant decreases were found in the OAS-M aggression scores (32.82±19.76 to 4.73±7.57, p=.000), subjective irritability scores (3.50±0.60 to 1.45±1.18, p=.000), and overt irritability scores (3.23±0.81 to 0.91±1.02, p=.000).

Conclusion: These results suggest that citalopram is an effective treatment for reducing impulsive aggressive behavior.

Volume: 64

Quick Links: Impulse-Control Disorders , Violence and Aggression

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Frontothalamic Circuit Abnormalities in Patients With Bipolar Depression and Suicide Attempts

To identify potential markers for suicide risk, this fMRI study looked at neural activity in bipolar depression...

Read More...